Krystal Biotech (NASDAQ:KRYS) Given New $215.00 Price Target at Citigroup

Krystal Biotech (NASDAQ:KRYS) had its price target hoisted by Citigroup from $206.00 to $215.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Citigroup’s target price points to a potential upside of 18.21% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Chardan Capital raised their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Stock Up 3.2 %

Shares of NASDAQ KRYS traded up $5.71 on Thursday, reaching $181.88. 293,635 shares of the company’s stock traded hands, compared to its average volume of 251,577. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The business’s 50 day simple moving average is $157.18 and its two-hundred day simple moving average is $175.18. The company has a market cap of $5.23 billion, a price-to-earnings ratio of 102.62 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same quarter last year, the firm earned $0.30 earnings per share. The business’s revenue for the quarter was up 116.4% on a year-over-year basis. Analysts forecast that Krystal Biotech will post 3.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 14.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech in the 3rd quarter worth approximately $40,000. Values First Advisors Inc. purchased a new position in shares of Krystal Biotech during the 3rd quarter worth $53,000. GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech during the 4th quarter worth $95,000. Huntington National Bank boosted its stake in shares of Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after acquiring an additional 283 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Krystal Biotech by 242.4% during the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after acquiring an additional 412 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).